Samsung Bioepis achieves double-digit growth in Q1, driven by biosimilars
Samsung Bioepis reported double-digit growth in Q1, with 454.9 billion won in revenue and 144 billion won in operating profit, driven by expanded biosimilar sales in Europe and the US.
Key takeaway
"Samsung Bioepis achieves double-digit growth in Q1, driven by biosimilars" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 45 out of 100. Samsung Bioepis reported double-digit growth in Q1, with 454.9 billion won in revenue and 144 billion won in operating profit, driven by expanded biosimilar sales in Europe and the US. Reported by Maeil Business on April 23, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.3%.